Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead product sales rise 36 per cent

Gilead product sales rise 36 per cent

28th January 2009

Gilead’s product sales have risen 36 per cent on the company’s 2007 figure, it has emerged.

Standing at $5.08 billion (3.56 billion pounds), the organisation’s figure was announced as part of the company’s its fourth-quarter and full year 2008 results, which declared total revenues reached $5.34 billion over the year, a 26 per cent increase on 12 months earlier.

The figures revealed the organisation’s Truvada sales also grew 25.1 per cent to $562.1 million over the final three months, while Atripla purchases rose 79 per cent $465.5 million over the same period.

Commenting on the results, the company said: “We recorded certain income tax benefits in the fourth quarter of 2008 that had the effect of increasing earnings by $0.04 per diluted share”.

The organisation went on to note non-generally accepted accounting principle research and development expenses were higher as a result of increased clinical study activity and a higher headcount.

In November last year, it was revealed two-year phase III trials of Gilead’s Viread found the drug induced “significant viral suppression”.

The product is used as a treatment for sufferers of chronic hepatitis B.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.